PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33429332-9	2021	However, these beneficial effects were greatly blocked by PPARgamma antagonist T0070907.	T 0070907	79-87	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	58-67	
35121022-9	2022	Specific inhibition of GPR120 by AH-7614 and PPARgamma by T0070907 reduced the EPA-or DHA-related attenuation of IL-1beta and NGF release.	T 0070907	58-66	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	45-54	
34295151-17	2021	PPAR-gamma selective inhibitor T0070907 abrogated QLY-induced MCP-1 production decline in LPS-primed pre-adipocytes and reduced adiponectin secretion.	T 0070907	31-39	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-10	
34305602-11	2021	It also significantly increased PPAR-gamma and SCD-1 expression, which can be abrogated by PPAR-gamma inhibitor T0070907.	T 0070907	112-120	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	32-42	
34305602-11	2021	It also significantly increased PPAR-gamma and SCD-1 expression, which can be abrogated by PPAR-gamma inhibitor T0070907.	T 0070907	112-120	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	91-101	
29439623-3	2018	In this study, we aimed to investigate whether aspirin could attenuate PPARgamma inhibitor (T0070907)-induced preeclampsia and its impact on expression of PPARgamma.	T 0070907	92-100	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	71-80	
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	T 0070907	56-64	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	20-29	
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	T 0070907	56-64	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	92-101	
32090669-9	2020	Interestingly, when PPARgamma activity was inhibited by T0070907, an effective and specific PPARgamma inhibitor, the therapeutic effect of EPO was significantly attenuated.Conclusion: Taken together, above results shown the protective effect of EPO on cyclosporine A-induced renal injury and confirmed that EPO"s anti-inflammation and antioxidative stress involving the PPAR gamma/TLR4/TGFbeta1 axis.	T 0070907	56-64	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	370-380	
31012948-11	2019	Moreover, in vitro CCK-8 effects were blocked by triciribine, a specific inhibitor of protein kinase B (Akt) and by the PPARgamma antagonist T0070907.	T 0070907	141-149	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	120-129	
31314916-10	2019	Moreover, the preadministration of the PPARgamma antagonist T0070907 or PPARgamma siRNA significantly attenuated GLT-1 up-regulation and the neuroprotective effects induced by IPC in vitro.	T 0070907	60-68	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	39-48	
29439623-3	2018	In this study, we aimed to investigate whether aspirin could attenuate PPARgamma inhibitor (T0070907)-induced preeclampsia and its impact on expression of PPARgamma.	T 0070907	92-100	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	155-164	
26703570-5	2015	Inhibition of PPARgamma activity by using its antagonist T0070907 and its specific siRNA oligonucleotides significantly attenuated the inhibitory effects of evodiamine on VSMC migration.	T 0070907	57-65	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	14-23	
27849367-8	2017	Treatment with the PPAR-gamma antagonist T0070907 reduced serum aldosterone compared to animals not exposed to DEHP in utero.	T 0070907	41-49	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	19-29	
23737070-5	2013	The specific inhibitors SB203580 (p38 MAPK inhibitor) and T0070907 (PPARgamma inhibitor) decreased the expression of adiponectin; however, compound C (AMPK inhibitor) did not significantly reduce the expression of adiponectin.	T 0070907	58-66	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	68-77	
18455351-8	2008	These protective effects were significantly reversed by the co-treatment with T0070907, a selective antagonist of the PPARgamma, which clearly demonstrated a PPARgamma-dependent mechanism.	T 0070907	78-86	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	118-127	
18455351-8	2008	These protective effects were significantly reversed by the co-treatment with T0070907, a selective antagonist of the PPARgamma, which clearly demonstrated a PPARgamma-dependent mechanism.	T 0070907	78-86	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	158-167	
16484917-0	2006	Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia.	T 0070907	72-80	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	0-48